Compare Stocks → Biden’s Sneaky H.R. 5376 Is A Nightmare For Retirement Savers (From Birch Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:EMMANYSE:IBIONASDAQ:TENXOTCMKTS:TRPXY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMMAEmmaus Life Sciences$0.11+10.0%$0.11$0.05▼$0.33$7.03M1.614,009 shs2,000 shsIBIOiBio$2.00+0.5%$0.00$1.02▼$22.20$6.96M-3.222.78 million shs39,370 shsTENXTenax Therapeutics$3.53-4.9%$3.91$3.45▼$61.20$6.92M2.25260,538 shs43,688 shsTRPXYTherapix Biosciences$6.03+0.5%$6.03$2.75▼$22.40$6.25MN/A12,316 shs53,500 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMMAEmmaus Life Sciences+10.00%+10.00%-0.90%-15.38%-64.25%IBIOiBio0.00%+19.88%-5.69%+198,999,900.00%+198,999,900.00%TENXTenax Therapeutics-2.34%+2.18%-1.83%-67.25%-85.58%TRPXYTherapix Biosciences0.00%0.00%0.00%0.00%0.00%$21,000 in profits in six weeks? (Ad)On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AN/AN/AN/ATENXTenax Therapeutics2.1536 of 5 stars3.55.00.00.00.00.01.3TRPXYTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMMAEmmaus Life SciencesN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/ATENXTenax Therapeutics3.00Buy$480.0013,497.73% UpsideTRPXYTherapix BiosciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest IBIO, TRPXY, EMMA, and TENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/20/2024TENXTenax TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMMAEmmaus Life Sciences$18.39M0.38N/AN/A($0.69) per share-0.16IBIOiBio$2.38M2.92N/AN/A$15.15 per share0.13TENXTenax TherapeuticsN/AN/AN/AN/A$27.15 per shareN/ATRPXYTherapix BiosciencesN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMMAEmmaus Life Sciences-$10.62M-$0.10N/A∞N/A-16.66%N/A-9.73%N/AIBIOiBio-$65.01MN/A0.00∞N/AN/A-150.59%-52.83%N/ATENXTenax Therapeutics-$7.71MN/A0.00N/AN/AN/A-65.79%-58.31%5/20/2024 (Estimated)TRPXYTherapix BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest IBIO, TRPXY, EMMA, and TENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/9/2024Q2 2024IBIOiBioN/A-$2.42-$2.42-$0.42N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ATRPXYTherapix BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMMAEmmaus Life SciencesN/A0.150.12IBIOiBio0.040.910.91TENXTenax TherapeuticsN/A3.263.26TRPXYTherapix BiosciencesN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMMAEmmaus Life Sciences7.42%IBIOiBio7.90%TENXTenax Therapeutics1.67%TRPXYTherapix BiosciencesN/AInsider OwnershipCompanyInsider OwnershipEMMAEmmaus Life Sciences35.00%IBIOiBio1.12%TENXTenax Therapeutics1.85%TRPXYTherapix BiosciencesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEMMAEmmaus Life Sciences5463.87 million41.51 millionNot OptionableIBIOiBio263.48 million3.45 millionN/ATENXTenax Therapeutics51.96 million1.92 millionNot OptionableTRPXYTherapix Biosciences81.04 millionN/ANot OptionableIBIO, TRPXY, EMMA, and TENX HeadlinesNo headlines for this company have been tracked by MarketBeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsEmmaus Life SciencesOTCMKTS:EMMAEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.iBioNYSE:IBIOiBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Tenax TherapeuticsNASDAQ:TENXTenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Therapix BiosciencesOTCMKTS:TRPXYTherapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Therapix Biosciences Ltd. has a collaboration with The University of Calgary to evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.